NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS).
To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/apellis-class-action-loss-submission-form/?id=43191&from=3
The lawsuit seeks to recover losses for shareholders who purchased Apellis between January 28, 2021 and July 28, 2023.
Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until October 2, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
According to a filed complaint, Apellis Pharmaceuticals, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
